Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate Treatment in Subjects with Severe Haemophilia A.

Trial Profile

Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate Treatment in Subjects with Severe Haemophilia A.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Haemophilia A
  • Focus Pharmacodynamics
  • Sponsors Bio Products Laboratory
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2017.
    • 12 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2017.
    • 12 Jul 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top